(Q46607347)

23 December 2017

title

Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States (English)

1 reference

23 December 2017

pneumococcal conjugate vaccine

main subject

United States of America

0 references

vaccine

0 references

1 reference

2

1 reference

23 December 2017

Keith P. Klugman

series ordinal

3

object named as

Keith P Klugman

1 reference

23 December 2017

G Thomas Ray

1

1 reference

23 December 2017

David R Strutton

series ordinal

4

1 reference

23 December 2017

Matthew R Moore

series ordinal

5

1 reference

23 December 2017

language of work or name

English

0 references

publication date

29 August 2009

1 reference

23 December 2017

number of pages

12

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

23 December 2017

volume

27

1 reference

23 December 2017

issue

47

1 reference

23 December 2017

page(s)

6483-6494

1 reference

23 December 2017

Policy Statement: Recommendations for the Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate Vaccine (Prevnar), Pneumococcal Polysaccharide Vaccine, and Antibiotic Prophylaxis

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Efficacy of a pneumococcal conjugate vaccine against acute otitis media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Efficacy of pneumococcal conjugate vaccines and their effect on carriage and antimicrobial resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Impact of a conjugate vaccine on community-wide carriage of nonsusceptible Streptococcus pneumoniae in Alaska

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Changing epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Population-based impact of pneumococcal conjugate vaccine in young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Uptake of pneumococcal conjugate vaccine among children in the 1998-2002 United States birth cohorts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

The promise of immunoprophylaxis for prevention of acute otitis media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Prevalence of Various Respiratory Viruses in the Middle Ear during Acute Otitis Media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Multinational study of pneumococcal serotypes causing acute otitis media in children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Effect of Community‐Wide Conjugate Pneumococcal Vaccine Use in Infancy on Nasopharyngeal Carriage through 3 Years of Age: A Cross‐Sectional Study in a High‐Risk Population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Seven valent pneumococcal conjugate vaccine immunization in two Boston communities: changes in serotypes and antimicrobial susceptibility among Streptococcus pneumoniae isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Epidemiology of community-acquired pneumonia in adult patients at the dawn of the 21st century: a prospective study on the Mediterranean coast of Spain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Effect of vaccine shortages on timeliness of pneumococcal conjugate vaccination: results from the 2001-2005 National Immunization Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Management of otitis media among children in a large health insurance plan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Utilization of services for otitis media by children enrolled in Medicaid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Impact of the pneumococcal conjugate vaccine on otitis media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

New vaccines against otitis media: projected benefits and cost-effectiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

Cost-effectiveness of pneumococcal vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.045

10.1016/J.VACCINE.2009.08.045

7 January 2021

Identifiers

DOI

1 reference

23 December 2017

PubMed ID

19720366

1 reference

23 December 2017